Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia
Emanuele Palomba, Maria Carrabba, Gianluca Zuglian, Laura Alagna, Paola Saltini, Valeria Fortina, Cinzia Hu, Alessandra Bandera, Giovanna Fabio, Andrea Gori, Antonio Muscatello
Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.
Topics & Concepts
MedicineAntibodyPandemicVirologyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Monoclonal antibodyDiseaseImmunologyPopulationCoronavirusInternal medicineInfectious disease (medical specialty)Environmental healthImmunodeficiency and Autoimmune DisordersBlood groups and transfusionImmune Cell Function and Interaction